Skip to main content
Japan Tissue Engineering Co., Ltd. logo

Japan Tissue Engineering Co., Ltd. — Investor Relations & Filings

Ticker · 7774 ISIN · JP3389610001 T Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2024-02-13 Interim / Quarterly Rep…
Country JP Japan
Listing T 7774

About Japan Tissue Engineering Co., Ltd.

https://www.jpte.co.jp/en/

Japan Tissue Engineering Co., Ltd. (J-TEC) is a company focused on the commercialization and industrialization of regenerative medicine. It develops, manufactures, and sells tissue-engineered medical products. The company operates through three primary business segments: the Regenerative Medicine Business, which provides its own therapeutic products such as autologous cultured cartilage and epidermis; the Custom Development & Manufacturing (CDMO) Business, offering contract services to support other developers in the field; and the LabCyte Business, which supplies cultured human tissue models for research and safety assessment purposes. J-TEC aims to establish regenerative medicine as a standard of care in healthcare.

Recent filings

Filing Released Lang Actions
四半期報告書－第26期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter (Q3) of the 26th fiscal period, filed by Japan Tissue Engineering Co., Ltd. with the Tokai Finance Bureau. It contains detailed financial statements, management analysis (MDA), and business status updates for the period from April 1, 2023, to December 31, 2023. This fits the definition of an Interim/Quarterly Report (IR). Q3 2024
2024-02-13 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text explicitly contains the title "第２四半期報告書" (Second Quarter Report) and specifies the reporting period: "第26期第２四半期（自2023年７月１日 至2023年９月30日）". This content structure, which includes confirmation by the CEO regarding the appropriateness of the filing according to financial instruments laws, is characteristic of a comprehensive interim financial report. Based on the definitions: - 10-K is for Annual Reports. - ER (Earnings Release) is for initial highlights. - IR (Interim/Quarterly Report) is for comprehensive reports for periods shorter than a year. Since this is a detailed Second Quarter Report, it fits the definition of an Interim / Quarterly Report (IR). The document length is short (601 chars), but it appears to be an excerpt or a cover/confirmation page *of* the report itself, rather than just an announcement *about* the report's publication (which would be RPA/RNS). The core content confirms the filing of the Q2 report.
2023-11-14 Japanese
四半期報告書－第26期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the second quarter of the 26th fiscal period, filed with the Tokai Finance Bureau on November 14, 2023. It contains detailed financial statements, management analysis (MDA), and business performance data for the period from April 1, 2023, to September 30, 2023. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. H1 2024
2023-11-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of the First Quarter Report (Q1). While it references the quarterly report, the document itself is a formal regulatory filing confirming the validity of the financial statements for the period ending June 30, 2023. Since it is a specific regulatory requirement for filing financial reports in Japan and does not fit into the other categories like 'IR' (which would be the report itself) or 'RPA' (as it is a formal legal confirmation rather than just an announcement), it is best classified as a Regulatory Filing.
2023-08-10 Japanese
四半期報告書－第26期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the first quarter of the 26th fiscal period (April 1, 2023, to June 30, 2023) for Japan Tissue Engineering Co., Ltd. It contains detailed financial statements, management analysis (MDA), and operational updates. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year that contains actual financial statements is classified as an Interim/Quarterly Report (IR). Q1 2024
2023-08-10 Japanese
内部統制報告書－第25期(2022/04/01－2023/03/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act in Japan. This type of report details the company's internal control framework, evaluation scope, and results regarding financial reporting. It is a formal regulatory filing required by Japanese law, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into the specific financial report categories like 10-K or IR, but is a mandatory regulatory submission.
2023-06-15 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.